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Abstract
The great interest for naked plasmid DNA in gene therapy studies is reflected by the fact that it is currently used
in 18% of all gene therapy trials. Therefore, validation of topology and functionality of DNA resulting from its
long-term stability is an essential requirement for safe and effective gene transfer. To this aim, we analyzed the
stability of good manufacturing practice–grade pCMVb reporter plasmid DNA by capillary gel electrophoresis,
agarose gel electrophoresis, and atomic force microscopy. The plasmid DNA was produced for a clinical gene
transfer study started in 2005 and was stored for meanwhile 7 years under continuously monitored conditions at
- 20C. The stability of plasmid DNA was monitored by LacZ transgene expression functional assays performed
in vitro and in vivo on the 7-year-old plasmid DNA samples compared with plasmid batches newly produced in
similar experimental conditions and quality standards. The analyses revealed that during the overall storage
time and conditions, the proportion of open circular and supercoiled or covalently closed circular forms is
conserved without linearization or degradation of the plasmid. The in vitro transfection and the in vivo jet-
injection of DNA showed unaltered functionality of the long-stored plasmid. In summary, the 7-year-old and the
newly produced plasmid samples showed similar topology and expression performance. Therefore, our stable
storage conditions are effective to preserve the integrity of the DNA to be used in clinical studies. This is an
important prerequisite for the long-term performance of gene transfer materials used in trials of long duration as
well as of the reference material used in standardization procedures and assays.
Introduction
Nonviral gene therapy vectors are of great impor-tance, and they are used in 18% of the total number of
clinical trials (Edelstein et al., 2007; Schleef et al., 2010; Ginn,
2013). This is because of their intrinsic biosafety characteristics
andmany technological improvements, which made nonviral
vectors a promising alternative over viral vectors in gene
therapy. The attractiveness of nonviral vectors is based on
their favorable characteristics, such as low toxicity and im-
munogenicity, in association with continuously improving
expression efficiencies (Gill et al., 2009; Tolmachov, 2009;
Haase et al., 2010). For the use of plasmid DNA in clinical
applications, there are two main requirements: the high
product purity and product stability for the final formulation.
Both are achieved by proper manufacturing and storage
conditions. The technology of large-scale production of plas-
mid DNA required for clinical applications has been signifi-
cantly improved since more than a decade (Schleef and
Blaesen, 2009; Schleef et al., 2010). This includes also the
progress made in plasmid purification, which is closely as-
sociated with improvements in long-term DNA stability
(Walther et al., 2003; Schleef and Bleasen, 2009). This progress
is paralleled with the development of physical transfer tech-
nologies of naked DNA, such as electroporation, particle
bombardment, jet-injection, and ultrasound (sonoporation),
which are often used to improve transfer efficiencies (Al-
Dosari andGao, 2009).With respect to the clinical use of plasmid
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DNA, the good manufacturing practice (GMP) guidelines
oblige high-quality standards not only concerning the pro-
duction process, but also during storage of the DNA at con-
trolled conditions. The appropriate storage of DNA batches is
essential to maintain constant and reliable quality, stability,
and functionality of the DNA. Ideally, the storage conditions
should preserve the GMP-grade DNA at those quality pa-
rameters, which were achieved at the time of the actual pro-
duction. For DNA vaccination studies, for instance, long-term
stability of plasmid DNA is a decisive factor for reproducible
clinical results (Lara and Ramirez, 2012). This is the essential
demand for the development of plasmid DNA-based phar-
maceuticals, which have to be stored and shipped under
controlled and documented conditions for long time, and the
DNA stability and functionality must be preserved during
storage (Zheng et al., 2011). In this context, only a few studies
exist, which analyze long-term stability parameters of un-
modified, naked plasmid DNA stored for more than 12
months. Such studies are of importance especially for plasmid
DNA in solution, since Voss et al. (2005) showed that its ly-
ophilization may negatively influence plasmid topologies. In
recent studies (PlasmidFactory, unpublished) the possibility
to lyophilize and resuspend plasmid DNAwas demonstrated
without damaging the supercoiled covalently closed circular
(ccc) form. However, the ability to completely resuspend the
DNA is mandatory and is highly dependent on DNA purity.
In an earlier study, we have shown that storage temperature
rather than the duration of storage is important to preserve
plasmid topology (Walther et al., 2003; Voss, 2007).
In this article, we extended our study in analyzing the
stability and functionality of the pCMVb reporter plasmid
DNA produced in 2005 for a phase I clinical study (De-
ReGe62) (Walther et al., 2008) and stored at 20C or lower, by
capillary and agarose gel electrophoresis (AGE), atomic force
microscopy (AFM), and reporter gene expression analyses
in vitro and in vivo compared with a fresh batch produced in
a comparable production process shortly before these ex-
periments have been performed.
Materials and Methods
Plasmid DNA
The Escherichia coli b-galactosidase (LacZ)–expressing
plasmid pCMVb (7,164 bp; Clontech) was produced and
tested in 2005 in collaboration with PlasmidFactory accord-
ing to the GMP guidelines for a phase I clinical gene transfer
trial (DeReGe 62) (Walther et al., 2008). In brief, transformed
E. coli were cultivated under controlled conditions by fer-
mentation. After alkaline lysis of harvested bacteria, plas-
mids were purified by a anion exchange chromatography
procedure. The resulting preparations were free of adventi-
tious bacteria and endotoxin, meeting the specifications
summarized in Table 1. The plasmid concentration was ad-
justed to 1lg/ll in 0.9% sodium chloride. At the time of
production, plasmid identity was confirmed by DNA se-
quencing, and plasmid topology was analyzed by capillary
gel electrophoresis (CGE). The unused, unopened sterile
batches of this plasmid DNA were stored for 7 years under
controlled conditions at less than or equal to - 20C at
PlasmidFactory’s GMP storage facility. For comparative an-
alyses, the same plasmid was recently produced by Plas-
midFactory, and quality standards were applied as state of
the art for the GMP production 7 years ago in order to
achieve comparability of the resulting DNA, meeting the
same specifications as defined for the GMP batch.
CGE analysis of plasmid topology
The CGE analyses of the different pCMVb plasmid batches
were performed to evaluate long-term stability of plasmid
DNA topology. The plasmid pUK21 (PlasmidFactory) was
used as a reference standard. CGE analyses were performed
using a Beckman P/ACE MDQ instrument equipped with an
laser induced fluorescence (LIF) detector (488/520nm) as de-
scribed (Schmidt, 1999; Walther, 2003). Briefly, coated capil-
laries (DB-17; J&WScientific)withaneffective lengthof30 cmto
the detector window, an inner diameter of 100lm, and a coat-
ing thickness of 0.1lm were used. The capillary was flushed
with a buffer solution, and just before analysis, the intercalating
dye YOYO (Molecular Probes) was added. After prestaining
with YOYO, the plasmid samples were introduced hydrody-
namically, and electrophoresiswas carriedout at 100V/cmand
30C. Peak surfaces were measured to quantify the amount of
each DNA forms, and data are presented in Table 2.
AGE analysis of plasmid topology
The various isoforms in a plasmid preparation were
made visible by AGE by using 250 ng plasmid DNA
Table 1. Specifications for the Good Manufacturing Practice Batch of 2005 as Applied
for the Newly-Produced Plasmid DNA Batch
Test Specification Analytical method
Appearance Clear, no visible particles Visual inspection
DNA concentration 1mg/ml ( – 5%) UV absorption 260 nm
DNA purity Peak at 258 nm UV scan (220–320 nm)
Plasmid identity Restriction pattern
conforms with DNA sequence.
Restriction digestion and AGE
RNA Not visible Visual inspection after AGE
Bacterial chromosomal DNA Not visible Visual inspection after AGE
DNA homogeneity (total ccc content) ‡ 90% ccc Capillary gel electrophoresis
Endotoxin (LPS) £ 100 E.U./mg DNA Quantitative Limulus amebocyte lysate assay
Protein < 10 lg/mg Bicinchoninic acid assay
Microorganisms < 1 CFU/ml Bioburden test
AGE, agarose gel electrophoresis; ccc, covalently closed circular; LPS, lipopolysaccharide endotoxin.
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electrophoresed through 0.8% agarose gels at 10 V/cm and
subsequently stained with 500 lg/ml ethidium bromide.
The fluorescent bands were made visible on a UV transil-
luminator at 312 nm. Although the electrophoretic mobil-
ity of different plasmid DNA structures may change
according to the electrophoresis conditions, in general, the
supercoiled ccc monomer forms move most rapidly, fol-
lowed by the open circular (oc) monomer forms and ccc
dimer forms. However, a clear distinction of the ccc dimers
and oc monomers is generally recognizable only in smaller
plasmids.
Endotoxin content (Limulus amebocyte lysate)
The gram-negative bacterial endotoxin content in a plas-
mid DNA solution was determined by the kinetic chromo-
genic test Kinetic–QCL Kinetic Chromogenic Assay (Lonza;
Prod. no. 50-650U) according to the manufacturer’s protocol.
Protein content (bicinchoninic acid assay)
The quantification of the total protein content in a plasmid
DNA solution is determined by the chromogenic test BCA
Protein Assay Kit (Pierce; Prod. no. 23227) according to the
manufacturer’s protocol.
AFM microscopy
The atomic force microscope is a versatile tool to map and
measure biological structures with high resolution and ac-
curacy at the nanometer scale (Anselmetti et al., 1994). Our
plasmid DNA molecules were visualized by AFM by using a
commercial instrument (Multimode AFM; Bruker) in AFM
tapping operation mode conditions. Briefly, the basic setup
consists of a microfabricated cantilever force sensor with an
integrated tip and a piezo scan tube on which the sample is
placed. By scanning the cantilever tip over the sample sur-
face, the topography can be visualized. Our DNA samples
were immobilized on a mica surface that has been functio-
nalized with aminopropyltriethoxysilane by gas-phase sila-
nization, rendering a smooth and homogeneously positively
charged surface (Lyubchenko et al., 1993). The molecules
were allowed to adsorb in the buffer solution for 10min.
Then, the surface was rinsed with ultrapure water and dried
in a clean jet of nitrogen gas.
Cells
The human SW480 cell line (colon carcinoma) was used
for functional analysis of the plasmid DNA in b-galactosidase
(LacZ) reporter gene expression assays. Cells were grown in
RPMI medium (Invitrogen), supplemented with 10% fetal
calf serum (Biochrom) at 37C in 5% CO2 incubator.
Transfection
About 4 · 105 cells were seeded into 6-well plates, and the
medium was supplemented with 2lg/well of the pCMVb
plasmid DNA using Fugene HD as recommended by the
manufacturer (Roche Diagnostics).
In vivo jet-injection
Female NMRI nu/nu mice xeno-transplanted with human
colon tumors (EPO GmbH) (Walther et al., 2001; Fichtner
et al., 2004) were used for nonviral in vivo jet-injection gene
transfer of the pCMVb plasmids. The mice were anesthetized
and received five jet-injections using the Jet-Injector (EMS
Medical GmbH) at a pressure of 3.0 bar through the skin
directly into the tumor (Walther et al., 2001). In each jet-
injection, 10ll of the plasmid solution containing 1mg/ml
of naked plasmid DNA was delivered. About 48 hr after
jet-injection, animals were sacrificed, and tumors were har-
vested and analyzed. The control animals received phos-
phate buffered saline (PBS) jet-injections. The animal
experiments were performed according to the German Ani-
mal Protection Law and with approval from the local au-
thorities (LaGeSo).
X-Gal staining
For cellular detection of LacZ expression in SW480 cells,
transfected cells were fixed in 2% paraformaldehyde for
10min at 4C, washed, and incubated with 3ml X-Gal mix
(1mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactoside [X-Gal],
1mM MgCl2, 3mM K3Fe[CN]6, and 3mM K4Fe[CN]6) for
24 hr at 37C in 6-well plates to allow blue staining. Cells
were washed with PBS and observed in a light microscope
(Zeiss), and microphotographs were taken.
For the detection of LacZ expression in vivo, animals were
euthanized 48 hr after jet-injection, and tumors were har-
vested for preparation of cryosections. The cryosections
(7lm) were fixed in 2% paraformaldehyde for 10min at 4C
and rinsed twice with ice-cold PBS. The slides were then
placed in quadriPERM plus chambers (Heraeus Instruments)
and covered with 3ml X-Gal mix for b-galactosidase detec-
tion. The cryosections were incubated for at least 24 hr at
37C and then covered in Faramount aqueous mounting
medium (Dako) for observation in a light microscope.
LacZ enzyme-linked immunosorbent assay
For quantification of LacZ expression, a LacZ enzyme-
linked immunosorbent assay (ELISA) was performed using
lysates from transfected SW480 cells. For the preparation of
cell lysates, cells were trypsinized and centrifuged, and re-
sulting cell pellets were incubated with a lysis buffer (Roche
Diagnostics) for 20min on ice and centrifuged at 12,000 rpm.
The clear supernatants were then subjected to the LacZ
ELISA (Roche Diagnostics), which was performed according
Table 2. Quality Control Analysis by Capillary Gel
Electrophoresis of 7-Year-Old Good Manufacturing
Practice Plasmid DNA Compared with Newly
Prepared Plasmid DNA
Topologies
GMP
plasmid
DNA (2005a)
7-year GMP
plasmid
DNA
New
plasmid
DNA
Percent ccc monomer 97.3a 91.9 91.9
Percent ccc dimer 5.0 6.3
Percent oc forms 2.7 3.1 1.8
The percentages are expressed as mean of two separate capillary
gel electrophoresis runs.
aThe data originate from the analysis performed in 2005, which at
this time did not distinguish between a ccc monomer and a ccc dimer.
GMP, Good Manufacturing Practice; oc, open circular.
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to the manufacturer’s instructions. The kit provides its own
standard reagent to generate reproducible standard curves.
The ELISA selectively detects only the bacterial protein, but
not endogenous b-galactosidase, with high sensitivity of
> 30pg/ml. For LacZ ELISA from tumor cryosections, serial
7 lm sections were incubated in the lysis buffer (Roche Di-
agnostics), centrifuged at 12,000 rpm, and subjected to the
ELISA. For each ELISA, standard curves were generated. The
absorbance was measured at 405 nm in a microplate reader
(Tecan). The respective b-galactosidase values were calcu-
lated using EasySoftG20/Easy-Fit software (Tecan) and
normalized to the protein concentration of the corresponding
lysate, which was determined by the Coomassie Plus Protein
Assay Reagent (Pierce). The standard curve was obtained
with serial dilutions of bovine serum albumin (1.25, 2.5, 5, 10,
12.5, 25, and 50mg/ml). The absorbance was measured at
595 nm in a microplate reader (Tecan).
Results and Discussion
Analyses of plasmid DNA topologies by CGE and AGE
In DNA-based pharmaceuticals, the stability of DNA and
the maintenance of its functionality are essential biosafety
requirements, especially for clinical applications. Therefore,
FIG. 1. Electropherograms of capillary gel
electrophoresis analysis (A, C) and agarose
gel electrophoresis (B, D) of the 7-year-old
pCMVb plasmid DNA (A, B) and of the
newly produced plasmid (C, D). M, 1 kbp
DNA ladder; pCMVb, plasmid DNA.
FIG. 2. AFM image of the 7-year-stored plasmid DNA. The
AFM image shows ccc plasmid DNA of different degrees of
condensation and oc forms (without linear forms, chromo-
somal DNA aggregates, or other contaminants). The figure
shows an AFM image with an edge size of 3lm. The altitude
of the DNA above the surface (in nm) is shown by different
colors as indicated on the bar on the right-hand side of the
AFM image. AFM, atomic force microscopy; ccc, covalently
closed circular; oc, open circular. Color images available
online at www.liebertpub.com/humc
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long-term storage of naked DNA, for instance, should be
done under controlled conditions in association with quality
controls of this DNA. In this study we analyzed the plasmid
DNA that was produced in 2005 in GMP conditions to be
used in a gene transfer clinical trial (Walther et al., 2008). We
compared the topology of this 7-year-old plasmid DNA with
that of newly produced DNA batches of the same plasmid.
Since DNA topology is easily and reliably detectable by
CGE, this method was used for the quantification of the
eventual topological variations (ccc vs. non-ccc) of the plas-
mid DNAs and the assessment of DNA quality (Schmidt
et al., 1999). CGE analysis defines plasmid isoforms by re-
spective peak migration, and area as area/migration time
ratio. Therefore, migration order in CGE analyses starts with
ccc monomer, ccc dimer, and possible linear forms, followed
by oc forms (monomer, dimer). Since the linearity between
plasmid DNA concentration and the peak area has been
demonstrated in previous studies, reliable quantitation of the
plasmid topologies is possible (Voss et al., 2003; Schleef and
Schmidt, 2004). Figure 1A and C shows the topology of the 7-
year-stored plasmid DNA compared with the newly pro-
duced one. Both CGE electropherograms reveal identical
profiles of the specific peaks of ccc monomer, ccc dimer, and
oc monomer, indicating thus that no degradation of the
plasmid DNA occurred. The values obtained from the peak
quantifications shown in Table 2 indicate identical percent-
ages for the ccc monomer (91.9% both) and only minor dif-
ferences in the ccc dimer (5% vs. 6.3%) and the oc monomer
(1.8% vs. 3.1%). At the time of plasmid production in 2005,
the CGE analysis revealed 96% for the ccc monomer,
FIG. 3. Functional in vitro and
in vivo tests of the 7-year-stored and
of the newly produced pCMVb
plasmid. The in vitro LacZ expres-
sion is quantified in the ELISA (A)
and visualized in vitro by X-gal
staining of transfected human colon
carcinoma SW480 cells, and empty
vector-transfected cells served as
negative control for the X-gal
staining (B). (C) Quantification of
the in vivo LacZ expression after
jet-injection gene transfer with
7-year-stored and newly prepared
plasmids. (D) In vivo LacZ expres-
sion, indicated as blue staining, in
the tumor tissues after intratumo-
ral jet-injection gene transfer with
7-year-stored and newly prepared
plasmids. Animals jet-injected with
phosphate buffered saline served as
negative control for X-gal staining.
Color images available online at
www.liebertpub.com/humc
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reflecting only a minor reduction by 4.1% during the 7-year
storage. More importantly, for both plasmid DNAs no linear
forms were detected. The AGE supports the CGE data,
particularly for possible degradation-related topologies of
the plasmid DNAs, which were not detectable for both
plasmids (Fig. 1B and D). These data indicate that even long-
term storage of naked plasmid DNA at controlled conditions
of - 20C preserves the plasmid topology as long as for 7
years and prevents the plasmid from degradation. This is of
primary importance when plasmid DNA is used for gene
therapy studies because it has been shown that ccc forms of
plasmid DNA are required for effective gene transfer com-
pared with oc or linearized forms (Remaut et al., 2006; Tol-
machov, 2009; Escoffre et al., 2012).
AFM analysis
The AFM is a valuable approach to analyze the plasmid
DNA structures and topologies at the molecular resolution
(Kim et al., 2011). In Fig. 2 the AFM top-view topography
image shows in detail the 7-year storage pCMVb plasmid
DNA in densely compacted ccc form. The ccc form can be
easily distinguished from open circular (oc) and linear forms.
The different superhelicity and coiling levels of the plasmids
result in different sizes of the condensed ccc plasmids up to
those being relaxed. Some molecules can be observed
showing nicked or linear forms. AFM visualizes also the
absence of contaminating material, such as solid particles or
aggregates of chromosomal DNA fragments, which are dif-
ficult to resolve and are potentially influencing the trans-
fection efficacy. Furthermore, the absence of bacterial
chromosomal DNA, nicked plasmids, and of non-DNA ma-
terial demonstrates that 0.2 lm filtration, which is done for
pharmaceutical-grade plasmid DNA, is an efficient proce-
dure to obtain pCMVb plasmid DNA. This is indeed a
valuable purification method for plasmid DNA preparations,
especially if they contain significant amounts of bacterial
chromosomal DNA resulting in aggregates of plasmid DNA
and large chromosomal DNA fragments.
Functional analyses of plasmid DNAs in vitro and in vivo
Besides preservation of DNA topology during long-term
storage, correct function regarding proper transgene ex-
pression is essential. Functionality of the 7-year plasmid and
of the newly produced plasmid was tested in vitro and
in vivo. The in vitro gene transfer with the pCMVb plasmids
was performed in SW480 human colon carcinoma cells. The
expression of the b-galactosidase reporter gene (LacZ) was
quantified in a LacZ-specific ELISA assay and evaluated in
cytochemical X-gal staining. The ELISA shows that, even
after long-term storage, LacZ expression is not declined
compared with the newly produced plasmid (492 ng LacZ/
mg protein vs. 345 ng LacZ/mg protein; Fig 3A). This is
further supported by the X-gal staining of transfected SW480
cells, showing similar transfection rates achieved with the 7-
year plasmid versus newly produced DNA (Fig. 3B). The
plasmid function was also tested in vivo using the nonviral
jet-injection gene transfer to apply the naked plasmid DNAs
intratumorally into subcutaneous xenotransplants of human
colon carcinoma (Walther, 2001). The LacZ expression was
detected qualitatively by histochemical X-gal staining in the
tumor cryosections. As shown, both plasmids exhibit effec-
tive LacZ expression in the tumors as blue-stained areas,
which is independent from their storage time (Fig. 3C,D).
The PBS control animals, however, show no staining for
LacZ expression, indicating specificity of the X-gal staining.
These in vitro and, more importantly, in vivo expression data
clearly demonstrate that even very long but controlled stable
storage conditions preserve the topology of naked plasmid
DNA and ensure effective and reproducible transgene
expression. The importance of stable storage conditions
was earlier shown for plasmid DNA stored at - 80C for 13
months (Walther, 2003). However, our current study signif-
icantly extends the earlier report, demonstrating that, after
7-year storage at - 20C, plasmid DNA topology and its
functionality for gene therapy applications are preserved at a
very high degree.
Conclusions
This study demonstrates that GMP-grade plasmid DNA
can be stored for very long time preserving a very high de-
gree of plasmid DNA topology (> 90%) and biological ac-
tivity in terms of transgene expression. The CGE and AFM
analyses revealed that storage of GMP-grade plasmid DNA
in a solution at thoroughly controlled conditions ( - 20C)
prevents degradation and preserves the applicability of
plasmid DNA as a pharmaceutical. In vitro and in vivo testing
of the 7-year-stored pCMVb plasmid DNA demonstrated
functional transgene expression in the b-galactosidase assay
and ELISA. Therefore, this study provides, for the first time,
strong indication that very long storage of plasmid DNA for
7 years does not limit its potential use for gene therapeutic
applications, which represents a decisive factor for design
and performance of clinical studies.
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